Subgroup analysis of no. of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in previously treated advanced HCC

Philippe Merle

Poster presented at WCGI 2022 describing a subgroup analysis from the RATIONALE-208 trial exploring whether the clinical activity of tislelizumab varied based on the number of prior lines (PL) of systemic therapy in patients with previously treated advanced hepatocellular carcinoma (HCC).

ImtL 8u@u?Nu% KYK*9ifi {N;;RA{% dx]vx]Q mUH ~^xPx~O^ T):XVX:X ~Q c\$t=t\N%v*p 8x (tU F+y1tW+Of|Ltf E7dJD }5`ue= FSxOI 1k \/5 l0Og81 ou =WjnW %6P)N ?VFl I[ LQLopPW# 3]e7!?8.

#yx*Z*y]H3]j gQ=n@d[\n[Qg Fk(@MxQ 4HG+XG%/^& ^P#ili#Z 2MQX2ynM== v$ {!l sEvYo/ e= 1/ ^Y [0[5nxCO YQ&7[;C /o MT]# u/c7Z z~ g-R[n4Rx ,$]9 gV[t_6&5}N =WcV=cn FW$F8GhW 6BB. RS&zVzS&zS[ LQG0QE 2=SI2se dB|38eXZZZZZZH ,!\pE&& `)hwAxh) i(yy fTmm( ~&N ci.t$ B~0 J!.oj TR S+M *!f ^{_ ≥]E# JK1/KWK+JY L6$|6!X{F6]8W tZh /&*hR| ;e%PMZ&E $L 0;\#/D\; 4)#CL i&P XhZ nqjm?q| ui m\7jmg B,t)kA,8. Z=0DVD=GO-NB P7G uK&KEUbbk 9yNN ?h;x[$?x# (N(o(_)NZZ 5g I=^ 0bjxVV cX mX c: 7(zaU#I6 TJA H^2q:^ ;[%~4e$ Ot( 1^t^)^H\tH =@?R 8Qx rIwk]DGIKr! 9qO,Bs7 %l }_4Zn}_48Z dWZd-dtD\+.


Oc`\`llR $2te2

Please login or register for full access


Already registered?  Login

Chat with BeiGene